Sheët .	1 of 1		J.	Rec'd PCT/F	7 763 PTO 2 P		
INFO	RMATION DISCLOSUR	ATTY. DOCK	ET NO.	ERIAL NO.	10 20	FEB. 2	001
	CITATION	1331-334	1	Unknown		#	5
		APPLICANT		-			De
(1	Jse several sheets if necessary)	VON BO					~ /
	ose several sheets if hecessary)	FILING DATE		GROUP		18	10%
		February	28, 2001			10)	40
		U.S. F	PATENT DOCUMENTS				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	01.400	011701.100		G DATE
PL	5,470,838	11/1995	NAME VAN BORSTEL	CLASS	SUBCLASS	IF APPH	OPRIAT
						_	
					ļ		
							
					-		
	<u> </u>	FORFIC	ON PATENT DOCUMENTS	<u> </u>	<u> </u>		
<u></u> -		- OTILIO	ATENT DOCUMENTS	y.		TRANS	LATION
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
							· · · · · · · · · · · · · · · · · · ·
					i i		
							<u> </u>
	OTHER DO	CUMENTS (inclu	ding Author, Title, Date, Pe	ertinent pages,	etc.)		
R	SECADES et al.; "CD	P-Choline: Pharr	nacoligical and Clinical Revi	ew. Methods an	etc.)	n Exper	imenta
PL	SECADES et al.; "CD and Clinical Pharmac	P-Choline: Pharr cology. 10/1995, \	nacoligical and Clinical Revi Vol. 17, Supplement 1, pp. 1-	ew. Methods ar 54	ıd Findings i		
	SECADES et al.; "CD and Clinical Pharmac Database Medline on	P-Choline: Phar cology. 10/1995, \ STN AN 940496	macoligical and Clinical Revi /ol. 17, Supplement 1, pp. 1- 98, KEILBAUGH et al. Anti-h	ew. Methods ar 54 uman Immunod	d Findings i	us tyne	1
-	SECADES et al.; "CD and Clinical Pharmac Database Medline on therapy and periphera model, by uridine and	DP-Choline: Pharm cology. 10/1995, V STN AN 940496: al neuropathy: pro I pyruvate. Molec	macoligical and Clinical Revi /ol. 17, Supplement 1, pp. 1- 98, KEILBAUGH et al. Anti-h evention of 2', 3'-dideoxy cyti ular Pharmacology. 10/1993	ew. Methods and 54 uman Immunod idine toxicity in F3. Vol. 44. No. 4	eficiency vire PC 12 cells, a 1, pp. 702-70	us type a neuroi	1 nal
PL PL B	SECADES et al.; "CD and Clinical Pharmac Database Medline on therapy and periphera model, by uridine and DYKENS, J.A. Isolat	OP-Choline: Pharmodology. 10/1995, No. 10/19	macoligical and Clinical Revi /ol. 17, Supplement 1, pp. 1- 98, KEILBAUGH et al. Anti-h evention of 2', 3'-dideoxy cyti ular Pharmacology. 10/1993 erebellar mitochondria produ	ew. Methods and 54 uman Immunod idine toxicity in F3. Vol. 44. No. 4 ce free radicals	eficiency vire PC 12 cells, a 1. pp. 702-70 when expos	us type a neuro 06	1 nal
PL PL PL	SECADES et al.; "CD and Clinical Pharmac Database Medline on therapy and periphera model, by uridine and DYKENS, J.A. Isolat Ca2+ and Na+: Impli	OP-Choline: Pharmodology. 10/1995, No. 10/19	macoligical and Clinical Revi Jol. 17, Supplement 1, pp. 1- 98, KEILBAUGH et al. Anti-he evention of 2', 3'-dideoxy cyti ular Pharmacology. 10/1993 erebellar mitochondria produ degeneration. Journal of Neu	ew. Methods and 154 uman Immunod idine toxicity in F3. Vol. 44. No. 41 ce free radicals urochemistry.	eficiency virue 12 cells, a ficiency virue 12 cells, a ficiency virue 12 cells, a ficiency virue 12 cells a ficiency virue v	us type a neuro 06 ed to el	1 nal evated
	SECADES et al.; "CD and Clinical Pharmac Database Medline on therapy and periphera model, by uridine and DYKENS, J.A. Isolat Ca2+ and Na+: Impli BODNAR et al. Resp	DP-Choline: Pharmodology. 10/1995, No. 10/19	macoligical and Clinical Revident 17, Supplement 1, pp. 1-98, KEILBAUGH et al. Anti-hervention of 2', 3'-dideoxy cyticular Pharmacology. 10/1993 are bellar mitochondria producted and fibroblasts exhibiting comman fibroblasts.	ew. Methods and 154 uman Immunod idine toxicity in F3. Vol. 44. No. 41 ce free radicals urochemistry.	eficiency virue 12 cells, a ficiency virue 12 cells, a ficiency virue 12 cells, a ficiency virue 12 cells a ficiency virue v	us type a neuro 06 ed to el	1 nal evated
	SECADES et al.; "CD and Clinical Pharmac Database Medline on therapy and periphera model, by uridine and DYKENS, J.A. Isolat Ca2+ and Na+: Impli	DP-Choline: Pharmodology. 10/1995, No. 10/19	macoligical and Clinical Revident 17, Supplement 1, pp. 1-98, KEILBAUGH et al. Anti-hervention of 2', 3'-dideoxy cyticular Pharmacology. 10/1993 are bellar mitochondria producted and fibroblasts exhibiting comman fibroblasts.	ew. Methods and 154 uman Immunod idine toxicity in F3. Vol. 44. No. 41 ce free radicals urochemistry.	eficiency virue 12 cells, a ficiency virue 12 cells, a ficiency virue 12 cells, a ficiency virue 12 cells a ficiency virue v	us type a neuro 06 ed to el	1 nal evated
	SECADES et al.; "CD and Clinical Pharmac Database Medline on therapy and periphera model, by uridine and DYKENS, J.A. Isolat Ca2+ and Na+: Impli BODNAR et al. Resp	DP-Choline: Pharmodology. 10/1995, No. 10/19	macoligical and Clinical Revident 17, Supplement 1, pp. 1-98, KEILBAUGH et al. Anti-hervention of 2', 3'-dideoxy cyticular Pharmacology. 10/1993 are bellar mitochondria producted and fibroblasts exhibiting comman fibroblasts.	ew. Methods and 154 uman Immunod idine toxicity in F3. Vol. 44. No. 41 ce free radicals urochemistry.	eficiency virue 12 cells, a ficiency virue 12 cells, a ficiency virue 12 cells, a ficiency virue 12 cells a ficiency virue v	us type a neuro 06 ed to el	1 nal evated
	SECADES et al.; "CD and Clinical Pharmac Database Medline on therapy and periphera model, by uridine and DYKENS, J.A. Isolat Ca2+ and Na+: Impli BODNAR et al. Resp	DP-Choline: Pharmodology. 10/1995, No. 10/19	macoligical and Clinical Revident 17, Supplement 1, pp. 1-98, KEILBAUGH et al. Anti-hervention of 2', 3'-dideoxy cyticular Pharmacology. 10/1993 are bellar mitochondria producted and fibroblasts exhibiting comman fibroblasts.	ew. Methods and 154 uman Immunod idine toxicity in F3. Vol. 44. No. 41 ce free radicals urochemistry.	eficiency virue 12 cells, a ficiency virue 12 cells, a ficiency virue 12 cells, a ficiency virue 12 cells a ficiency virue v	us type a neuro 06 ed to el	1 nal evated
-	SECADES et al.; "CD and Clinical Pharmac Database Medline on therapy and periphera model, by uridine and DYKENS, J.A. Isolat Ca2+ and Na+: Impli BODNAR et al. Resp	DP-Choline: Pharmodology. 10/1995, No. 10/19	macoligical and Clinical Revident 17, Supplement 1, pp. 1-98, KEILBAUGH et al. Anti-hervention of 2', 3'-dideoxy cyticular Pharmacology. 10/1993 are bellar mitochondria producted and fibroblasts exhibiting comman fibroblasts.	ew. Methods and 54 comman Immunod idine toxicity in F3. Vol. 44. No. 40 comments of the free radicals arochemistry. 19 defective mitochemistry.	eficiency virue 12 cells, a ficiency virue 12 cells, a ficiency virue 12 cells, a ficiency virue 12 cells a ficiency virue v	us type a neuro 06 ed to el	1 nal evated 4-591

INFOF	RMATION DISCLOSURE	ATTY. DOCKET NO.		SERIAL NO.	Γ.		
	CITATION	1331-334	1331-334		<i>ii</i> (
	01	PARPLICANT		09/763,955	N. S.	Œ	1:1
		VON BORST	EL		Ħ	0	()
(U	se several sheets if necessary	7 MILING DATE		GROUP	<u></u>	9	111
	R	February 28, 2	2001		60	20	
	DOCUMENT NUMBER	U.S. PATE	NT DOCUMENTS		17ER 1600/29005S	21	$\overline{\Pi}$
EXAMINER	RAU	EMARK		a.		FILIN	GDATE
INITIAL D/	DOCUMENT NUMBER 6,258,795	7/2001	NAME von Borstel et al	CLASS	SUBCLASS	IF APRI	HOPRIAT
- pc	0,200,700	772001	7011 2010(01 01 41				
····							-
			· -			ļ	. .
					<u> </u>		
					<u> </u>		
		FOREIGN PA	TENT DOCUMENTS		<u> </u>		
							SLATION
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
							+
			ne water.			<u> </u>	+
					<u> </u>		
-							1
	OTHER DOC	UMENTS (including	Author, Title, Date, P	ertinent pages.	etc.)		
	- Naviaux et al, "Clinical	experience with uridi	ne and triacetyluridine	(PN401) therapy	of mitochor		
	abstract in meeting pro		al-Dysfunction in Hum	an Pathology, S e	ptember 5-7	7 , 19 98	<u>, H</u> òtel
	Sofitel, Melbourne, Au	stralia			<u>.</u>		
· · · - · · · ·				·			
							
xaminer	1//	/	Date Considere	ed 10 - 19	- 25		

INFORM	MATION DISCLOSUF	ATTY. DOCK	ET NO.	SERIAL NO.	CH CENTER 16	`C	
ا ما	CITATION	1931-334		09/763,955	CH AN	<u>, ()</u>	La
		APPLICANT			CANTO.	32	\
(Use	several sheets if necessary)	VON BO		GROUP		<u> </u>	
				anoor	~	020	
		February U.S. F	PATENT DOCUMENTS			-00	
XAMINER INITIAL	DOCUMENT NUMBER		NAME	CLASS	SUBCLASS	FILING	
PL	6,316,426	11/2001	von Borstel et al		-		911111
						j	
				-			
					:		
:							
		 	· · · · · · · · · · · · · · · · · · ·				<u></u>
							
		FOREIG	ON PATENT DOCUMENTS				
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANS YES	LATIC NO
							
							-
			,				<u> </u>
L	OTHER DO	OCUMENTS (in all	iding Author, Title, Date, P	Portinent pages	oto)		<u> </u>
	- Fapes (2) of Mitoch	ondrial Dysfunction	n in Human Pathology confe	rence, Monday, S	etc.) Sept. 7, 1996	3 afterno	oon
	session, Melbourne,	Australia; particul	arly-Dr. Naviaux's presentat	ion, second-one,	side A	Dogodk	- of t
	University of Californ	Declaration of will nia's Opposition to	liam L. Nyhan, M.D., Ph.D. Plaintiff Pro Neuron Inc.'s N	m-Supp o n оныен Motion for Prelimir	pary Injuncti	negenis on.	20U
		····					

Examiner: Initial it reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

*Examiner Date Considered 0-/9-03

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Sheet	1 f • 1						
INFOR	MATION DISCLOSURE	ATTY.	DOCKET NO. SERIA	AL NO.			
	MATION DISCLOSURE CITATION PE	1331	-334 · 09/7	63,955			
	/ -	APPLIC	CANT	05,755			
	-50 1 4 2002	WON.	BORSTEL				
(Use	e several sheets if necessary)	VON FILING	DATE GROU	JP			
	e several sheats if necessary)	Eobr	nory 28, 2001				
	° Votation at a	reun	uary 28, 2001 J.S. PATENT DOCUMENTS				
*EXAMINER			J.S. PATENT DOCUMENTS	-		FILING	DATE
INITIAL	DOCUMENT NUMBER	DATE	NAME Debank	CLASS	SUBCLASS	IF APPR	OPRIATE
	60/121,588		Naviaux, Rebert K				23/99-
					;		
				 			
					- I\		
					EIVE[)	
				rrn	2 0 2002		
				PEB	6 0 2002		
				│ ^! 	100 +600/2	<u> </u>	
			IE	TH CENT	ER 1600/2	500	
				<u> </u>			
						<u> </u>	
		FC	DREIGN PATENT DOCUMENTS	•	•		
							LATION
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
				-		-	-
			7	<u> </u>		-	1
				 			
-							
-							
				·			
	OTHER DOO	CUMENTS (including Author, Title, Date, Pertinen	t pages,	etc.)		
,	December 9, 2001 De	claration of	Robert Naviaux, M.D. in Support of Defe tiff Pro-Neuron Inc.'s Application for Tem	≀ndant≅Th	e Regents of	of the Ur	niversity 1 Order
				-			

Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

*Examiner

INFORM	TATION DISCLOSURE CITATION		OCKET NO.		OO /		REC	EIV	ED
100		1331 APPLIC	-334 ANT		09//	63,95	5 HIN 4	2 4 20	n 2
67			BORSTEL				JUN	£ £ € €	JC
2 9 2002	several sheets if necessary)	FILING I	DATE		GROUP	2	ECH CENT	ER 160	10/290
			uary 28, 200		··				
EXAMINER	<u> </u>	U	.S. PATENT D	OCUMENTS				EII ING	DATE
INITIAL	DOCUMENT NUMBER	DATE		NAME		CLASS	SUBCLASS		
						-			
								\	
						<u> </u>	EULI	VLL)
							MAY 3-0		
						TECH	CENTER	600/29	00
		FO	REIGN PATEN	IT DOCUMENT	rs				
	DOCUMENT	DATE		COUNTRY		CLASS	SUBCLASS	TRANS YES	LATIOI NO
	OTHER DOO	UMENTS (i	including Auth	or, Title, Date	, Pertinent	pages,	etc.)		
	Letter dated July 27,	998 from R	obert K. Navi at	ıx to the U.S. F	ood and Dr	ug Admi	nistration-(F	DA)	
			400.5						
				-					
		-							
						\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \			
Examiner	1111-11-			Date Conside	erea I 🖊	トノソン	9 8		

<i>و</i> ز د	1 3 2002 (Use several sheets if necessary)		DOCKET NO. -334	SERIAL NO. 09/763,955		SEIV 1.8.2	
1 3 2002 (Use			BORSTEL DATE LIARY 28, 2001	GROUP	TECH CEN	NTER 16	00/2
			J.S. PATENT DOCUMENTS				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPR	
-							
			ADEION BATENT BOOKSEN	<u> </u>			
		FC	PREIGN PATENT DOCUMENT	<u>S</u>	-	TRANS	LATIC
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	N
							<u> </u>
					1		ļ
						-	
	OTHER DOC	JMENTS (including Author, Title, Date,	Pertinent pages,	etc.)		
•	First Amended Cross-C Naviaux; 07/26/02; pag		of Defendants The Regents of	the University of C	alifornia and	Dr. Ro	pert l
	Scoond Amonded Com	plaint of F	laintiff-Wellstat-Therapeutics-C	ornoration (f/k/a/ F	ro-Neuron I	nc): 08.	21/0

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

*Examiner

Date Considered

Shcet	1.	,		/	70112				‡	
INFO	RMA	. JISCLOSURE ATION		-334	APR 0 7 2003	SERIA 09/70	L NO. 63,955	, ;		
(L	Jse sev	reral sheets if necessary)	FILING	BORSTE		GROU 1623			₩ °	
	<u> </u>				DOCUMENTS	1023)		Ö	
*EXAMINEI	3			J.J. FATEN	DOCOMENTS				FILING	G DATE
INITIAL		6,472,378	DATE 10/2002		NAME von Borstel		CLASS	SUBCLASS	IF APPR	OPRIATE
	11		FOR	REIGN PATE	NT DOCUMENTS				1	
	·	DOCUMENT	DATE		COUNTRY		CLASS	SUBCLASS	TRANS YES	SLATION NO
										T
									<u> </u>	
								<u> </u>	<u></u>	<u> </u>
		OTHER DOCU Copy of Current Claims Reference 1331-352).			thor, Title, Date, Poplication Serial No.)1; (Atto	rney
		Copy of Current Claims (Attorney Reference 133	1-337) .							
PL		Morais, R., and Guertin, genome to the growth of Morias, R., et al, <u>In Vitr</u> e	Chinese ha	mster embryo	cells in culture"					
		Characterization of Cont						, , , , , , , , , , , , , , , , , , , ,		
		Bourgeron, Thomas, et a and expression of the de virus-transformed lymph	leted mitoch	ondrial DNA						
		Löffler, Monika, et al, <u>M</u> oxidoreductase links mit					'Dihydroo	orotat-ubiqui	none	
	i	Page, Theodore, et al, Prassociated with increased	oc. Natl. Ac I cellular nu	ad. Sci. USA, icleotidase acti	vol. 94, pp. 11601-1 vity"		ber 1997,	"Developme	ental disc	order
	\rightarrow	Keilbaugh et al (Mol. Ph				240	1	47 (100)	2)	
		Kralovansky et al, "Cand					ostract, li	nes 4-7 (199.	<i>)).</i>	
		Lipp et al, Biology of the Sartori et al, Alcohol 3:9								
-NI		Agnati et al, Acta Phys.								
	+	i ignati ot al, ricia i llys.		. 555 551, 500	2000 act, 111103 5-15 (

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

*Examiner

Sheet 1								
INFORM	ATION DISCLOSURE		OCKET NO.	SERIAL				
_	CITATION	1331-3		09/76	53,955		<u> </u>	
E/		APPLICA						
<u>خ)</u>			BORSTEL					
2003 Subse si	everal sheets if necessary)	FILING D	ATE	GROUF	•			
		Februa	ary 28, 2001	1623				· · · · ·
ABKOF		U.S	S. PATENT DOCUMENTS	;				
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS		G DATE
1	5,968,914	10/1999	von Borstel et al.					_
			Market Market					
						<u> </u>	-	
<u></u>	1							
						<u> </u>		
						当	<u> </u>	71
						N. N.	PR	M
						一計	8	0
						=======================================	8 2	111
						S S	2003	\leq
			·····			1600/2900		8
						9		
		FORE	EIGN PATENT DOCUMEN	ITS				
			1.11.111111					SLATION
	DOCUMENT	DATE	COUNTRY		CLASS	SUBCLASS	YES	NO
 								
			<u> </u>					
	OTHER DOCU	IMENTS (inc	luding Author, Title, Date	e, Pertinent p	ages, e	tc.)		L
01	Chen et al; "Effect of Ar	ti-Human Imi	nunodeficiency Virus Nucleo	side Analogs o			and Its	
15	Implication for Delayed	Toxicity"; Mo	olec. Pharmacol; 39:625-628; odeficiency Virus Type 1 The	(1991).	haral Mai	ronathu. Dra	wantian	of 21 21
PL PL			ls, a Neuronal Model, by Urio					

Examiner: Initial if reprence considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

*Examiner

9	Sheet 1			,			
3	INFORMATION DISCLOSURE		ATTY.	DOCKET NO.	SERIAL-NO.	SIVED	
		CITATION		1331-334		HAY 27 2003	
(P	<i>∞</i> }		APPLIC	CANT		an rew	
			VON	BORSTEL		MAY LI 200	
N 2	3 5003 FF	e several sheets if necessary)	FILING	DATE	GROUP	TECH CENTER 1600/2900	
	. \$	e several sheets if necessary)	Febru	uary 28, 2001	1623	TECH CENTER	
ZRAI	EMARK			J.S. PATENT DOCUMENTS			
Ξ,	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	FILING DATE SUBCLASS IF APPROPRIATI	
_	r	2002/0028787 A1	03/2002	Watkins et al			
_							
-					-		
-					- <u>-</u>		
-							
-							
_							
_							
-							
-							
_						_	
-							

FOREIGN PATENT DOCUMENTS DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO WO 00/06174 02/2000 WIPO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

*Examiner: Initial ideference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.